TOP2A and gonorrhea: Zoliflodacin, a novel spiropyrimidinetrione being developed for the treatment of Neisseria gonorrhoeae infections and is in phase III clinical trials, interferes with bacterial DNA synthesis by binding to DNA gyrase at a site different from that of fluoroquinolines (48).